Efficacy and Safety of HSK31679 in Asian Patients with MASLD: A Randomized Controlled Trial

IF 12 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Clinical Gastroenterology and Hepatology Pub Date : 2025-08-20 DOI:10.1016/j.cgh.2025.08.009

Feng Xue, Wei Ma, Jixian Gao, Jinjun Chen, Wei Yue, Peili Bu, Qincong Chen, Hao Chen, Jianlong Sheng, Liang Chen, Fei Liu, Guangming Li, Chuanwu Zhu, Bihui Zhong, Jianming Zhang, Qingxian Cai, Le Wang, Ying Chen, Zhaohui Pei, Lvfeng Yao, Lingchun Lv, Yanhang Gao, Bihua Xia, Xianyou Ji, Yang Liu, Laijing Du, Genshan Ma, Kunyan Hao, Fangqiong Li, Tingting Wu, Yong Huo, Lai Wei

引用次数: 0

Abstract

This study evaluated the efficacy and safety of the thyroid hormone receptor β agonist HSK31679 in Asian patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

查看原文本刊更多论文

HSK31679在亚洲MASLD患者中的疗效和安全性：一项随机对照试验

本研究评估了甲状腺激素受体β激动剂HSK31679在亚洲代谢功能障碍相关脂肪变性肝病（MASLD）患者中的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Gastroenterology and Hepatology 医学-胃肠肝病学

CiteScore

16.90

自引率

4.80%

发文量

903

审稿时长

22 days

期刊介绍： Clinical Gastroenterology and Hepatology (CGH) is dedicated to offering readers a comprehensive exploration of themes in clinical gastroenterology and hepatology. Encompassing diagnostic, endoscopic, interventional, and therapeutic advances, the journal covers areas such as cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption, and secretion. As a peer-reviewed publication, CGH features original articles and scholarly reviews, ensuring immediate relevance to the practice of gastroenterology and hepatology. Beyond peer-reviewed content, the journal includes invited key reviews and articles on endoscopy/practice-based technology, health-care policy, and practice management. Multimedia elements, including images, video abstracts, and podcasts, enhance the reader's experience. CGH remains actively engaged with its audience through updates and commentary shared via platforms such as Facebook and Twitter.